SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-007994
Filing Date
2023-03-17
Accepted
2023-03-16 21:29:12
Documents
58
Period of Report
2023-01-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 861547
2 ex31-1.htm EX-31.1 16481
3 ex31-2.htm EX-31.2 16971
4 ex32-1.htm EX-32.1 6935
5 ex32-2.htm EX-32.2 6663
  Complete submission text file 0001493152-23-007994.txt   4242009

Data Files

Seq Description Document Type Size
6 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT anix-20230131.xsd EX-101.SCH 29630
7 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT anix-20230131_cal.xml EX-101.CAL 39671
8 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT anix-20230131_def.xml EX-101.DEF 122618
9 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT anix-20230131_lab.xml EX-101.LAB 244123
10 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT anix-20230131_pre.xml EX-101.PRE 191315
52 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 722332
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

IRS No.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-37492 | Film No.: 23740540
SIC: 2834 Pharmaceutical Preparations